Vertero

Vertero is building a focused pipeline of novel small molecule therapeutics for peripheral drivers of neurogenerative diseases, aiming to bring new hope to affected communities.

Parkinson’s gut-microbiota links raise treatment possibilities

The company aims to deliver oral therapeutics intended to help preserve patient functionality and independence and improve long-term outcomes.

First participant with Parkinson’s disease dosed at the Centre for Human Drug Research in the Netherlands

Life sciences veteran joins Vertero’s executive leadership team to drive strategic partnerships and accelerate portfolio strategy in neurodegenerative disease

Renowned global leaders will guide scientific strategy in Parkinson’s disease and beyond as company enters clinical development

VT-5006 is a first-in-class small molecule designed to precisely engage a validated peripheral target to delay onset and slow progression of Parkinson’s disease

The company says its discoveries target causative mechanisms in the peripheral nervous system, outside the brain, rather than symptoms.

Vertero Therapeutics, Inc. 400 Tradecenter Drive, Suite 5900 Woburn, MA 01801

First Patient with Parkinson’s Disease Dosed in Phase 1b Clinical Study of VT-5006

The Privacy Statement describes the information collected on the website, how it is used and protected, and the choices available to users. It states that the company upholds applicable data protection laws and regulations, including the GDPR.

Vertero Therapeutics, Inc. owns and maintains the website for information and general education. Its Terms of Use govern access to the site and its contents.